Longtime biotech investor injects $250M into Palo Alto company a year after IPO
December 02, 2019 at 09:51 AM EST
Kodiak Sciences is in a pivotal trial with its lead drug against a blinding eye disease.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|